Imaging dopamine's role in drug abuse and addiction
CVS Caremark ) are proceeding through federal courts, but these don't affect Wegovy's preferred status
Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
We highlight how single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics have unveiled unprecedented cellular heterogeneity, delineated pathogenic trajectories like maladaptive tubular cell states, and established immune dysregulation as central to disease progression
These combination approaches raise important questions about receptor saturation, cumulative side effects, and whether dual agonism produces additive or synergistic outcomes
